AR058266A1 - Derivados espirociclicos inhibidores de pde7 y su aplicacion terapeutica - Google Patents

Derivados espirociclicos inhibidores de pde7 y su aplicacion terapeutica

Info

Publication number
AR058266A1
AR058266A1 ARP060105332A ARP060105332A AR058266A1 AR 058266 A1 AR058266 A1 AR 058266A1 AR P060105332 A ARP060105332 A AR P060105332A AR P060105332 A ARP060105332 A AR P060105332A AR 058266 A1 AR058266 A1 AR 058266A1
Authority
AR
Argentina
Prior art keywords
spirociclic
derivatives
therapeutic application
pde7
pde7 inhibiting
Prior art date
Application number
ARP060105332A
Other languages
English (en)
Inventor
David J Rawson
Nigel A Swain
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AR058266A1 publication Critical patent/AR058266A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente proporciona compuestos de formula (1) en la que m es 0, 1 o 2; X es O, S o N-CN; R es F, Cl o CN; A es un grupo cicloalquileno C3-6 opcionalmente sustituido con un grupo alquilo C1-4; y B es un enlace sencillo o un grupo alquileno C1-2; o una de sus sales, solvatos, polimorfismos o profármacos farmacéuticamente aceptable. Los compuestos son inhibidores de PDE7 y tienen una diversidad de aplicaciones terapéuticas, particularmente en el tratamiento del dolor, especialmente dolor neuropático.
ARP060105332A 2005-12-02 2006-12-01 Derivados espirociclicos inhibidores de pde7 y su aplicacion terapeutica AR058266A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74185405P 2005-12-02 2005-12-02
US79118606P 2006-04-10 2006-04-10

Publications (1)

Publication Number Publication Date
AR058266A1 true AR058266A1 (es) 2008-01-30

Family

ID=37882213

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105332A AR058266A1 (es) 2005-12-02 2006-12-01 Derivados espirociclicos inhibidores de pde7 y su aplicacion terapeutica

Country Status (22)

Country Link
US (1) US7507742B2 (es)
EP (1) EP1957467A2 (es)
JP (1) JP2009517453A (es)
KR (1) KR101009554B1 (es)
AP (1) AP2008004470A0 (es)
AR (1) AR058266A1 (es)
AU (1) AU2006321349A1 (es)
BR (1) BRPI0619126A2 (es)
CA (1) CA2631535C (es)
CR (1) CR10039A (es)
EA (1) EA200801145A1 (es)
EC (1) ECSP088484A (es)
GT (1) GT200600494A (es)
MA (1) MA30014B1 (es)
ME (1) MEP0408A (es)
NL (1) NL2000336C2 (es)
NO (1) NO20082077L (es)
PE (1) PE20071087A1 (es)
RS (1) RS20080233A (es)
TW (1) TW200732307A (es)
UY (1) UY29979A1 (es)
WO (1) WO2007063391A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9710536A (pt) 1996-07-24 1999-08-17 Warner Lambert Co Isobutilgaba e seus derivados para o tratamento da dor
BRPI0609879A2 (pt) * 2005-04-28 2010-05-11 Pfizer Ltd derivados de aminoácidos
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
CA2681650C (en) * 2007-03-27 2016-11-22 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
CA2687944A1 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
AR076590A1 (es) * 2009-05-19 2011-06-22 Vivia Biotech Sl Metodos para proveer pruebas medicinales personalizada ex vivo para neoplasmas hematologicos
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
RU2661410C2 (ru) 2010-11-08 2018-07-16 Омерос Корпорейшн Лечение зависимости и расстройства побуждений с применением ингибиторов фдэ7
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
CA3069432A1 (en) 2017-07-12 2019-01-17 Dart Neuroscience, Llc Substituted benzoxazole and benzofuran compounds as pde7 inhibitors
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138815A1 (en) 2000-04-28 2003-07-24 Franz-Werner Kluxen Splice variant of camp phosphodiesterase type7(pde7a3)
WO2002076953A1 (en) 2001-03-21 2002-10-03 Warner-Lambert Company Llc New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
CA2599662A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain

Also Published As

Publication number Publication date
AU2006321349A1 (en) 2007-06-07
RS20080233A (en) 2009-07-15
NL2000336A1 (nl) 2007-06-05
NL2000336C2 (nl) 2007-08-07
KR101009554B1 (ko) 2011-01-18
WO2007063391A3 (en) 2007-09-13
CA2631535A1 (en) 2007-06-07
US7507742B2 (en) 2009-03-24
KR20080059338A (ko) 2008-06-26
CR10039A (es) 2008-07-10
EP1957467A2 (en) 2008-08-20
EA200801145A1 (ru) 2008-10-30
MEP0408A (xx) 2010-02-10
GT200600494A (es) 2007-07-06
UY29979A1 (es) 2007-06-29
US20070129388A1 (en) 2007-06-07
PE20071087A1 (es) 2007-12-29
JP2009517453A (ja) 2009-04-30
TW200732307A (en) 2007-09-01
ECSP088484A (es) 2008-06-30
WO2007063391A2 (en) 2007-06-07
CA2631535C (en) 2010-07-27
NO20082077L (no) 2008-06-04
AP2008004470A0 (en) 2008-06-30
MA30014B1 (fr) 2008-12-01
BRPI0619126A2 (pt) 2011-09-13

Similar Documents

Publication Publication Date Title
AR058266A1 (es) Derivados espirociclicos inhibidores de pde7 y su aplicacion terapeutica
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
ATE536349T1 (de) In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
HN2009003002A (es) Compuestos de piridopirimidinonas inhibidores de pi3k-alfa
UY32138A (es) Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
CY1109732T1 (el) Χρησις παραγωγων βενζο-συνενωμενου ετεροκυκλο σουλφαμιδιου δια την θεραπειαν πονου
DE602004031037D1 (de) Heterocyclische inhibitoren von mek
AR025976A1 (es) Inhibidores de fab i.
ECSP099376A (es) Inhibidores de la actividad de la akt
ECSP034896A (es) Derivados aromaticos de acidos dicarboxilicos
NO20052787L (no) N-alkyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
NI200700320A (es) Inhibidores de la actividad akt
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
SE0301888D0 (sv) New use VII
NO20052788L (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
DK1709044T3 (da) Oxazolidinon-quinolon-hybridantibiotika
UY30787A1 (es) "inhibidores benzoimidazolicos de trpv1"
IT1319202B1 (it) Farmaci per le malattie a base infiammatoria.
DOP2006000279A (es) Derivados espirocíclicos
AR057403A1 (es) 4- anilino-3-quinolincarbonitrilos para el tratamiento del cancer
EA200600549A1 (ru) Ингибиторы каспаз в качестве материала для покрытия медицинских продуктов для ингибирования рестеноза
UY26329A1 (es) Antagonistas de los receptores de vitronectina

Legal Events

Date Code Title Description
FB Suspension of granting procedure